Patent ID: 8252842
Filing Date: 2012-08-28
Classification: A61P,C07B,C07C

Abstract:
1. A method of treating a MEK mediated disorder, wherein prevention is excluded, comprising administering to an individual in need thereof a therapeutically-effective amount of a crystalline polymorph of N—(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide having at least one of the following properties: (a) a powder x-ray diffraction pattern substantially the same as the powder x-ray diffraction pattern shown in (b) a differential scanning calorimetry pattern substantially the same as the a differential scanning calorimetry pattern shown in or (c) a melting point onset as determined by differential scanning calorimetry at about 143° C. for said crystalline polymorph.